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ABSTRACT
Background The social determinants of health are a 
decisive yet persistently understudied area for tackling 
global health challenges like antimicrobial resistance 
(AMR). Precarity is one determinant whose importance is 
increasingly recognised, which we define here as ‘a form 
of pernicious self- dependence that undermines individuals’ 
control over their own lives and limits their ability to 
flexibly respond to crises’. We aimed to assess the 
relationship between precarity, other forms of deprivation 
and healthcare- seeking behaviour by asking, ‘What 
is the impact of precarity, marginalisation and clinical 
presentation on healthcare- seeking behaviour?’ and ‘Do 
patients experiencing precarious livelihoods have clinically 
less advisable healthcare- seeking behaviour?’
Methods We used healthcare- seeking behaviour census 
survey data from rural Thailand and Laos, wherein five 
rural communities were surveyed two times over a period 
of 3 months (2- month recall period). Using descriptive 
statistical and multivariate logistic regression analysis on 
the illness level, we studied precarity alongside clinical 
presentation, marginalisation and facilitating solutions 
during an illness (eg, health- related phone use) as 
determinants of healthcare- seeking behaviour in the form 
of healthcare access and antibiotic use.
Results The data included 1421 illness episodes from 
2066 villagers. Patients in precarious circumstances 
were up to 44.9 percentage points more likely to misuse 
antibiotics in the presence of situational facilitators 
(predicted antibiotic misuse: 6.2% (95% CI: 0.9% to 
11.4%) vs 51.1% (95% CI: 16.6% to 85.5%) for precarious 
circumstances with/without facilitation). Marginalisation 
was linked to lower antibiotic use, but this did not 
translate into clinically more advisable behaviour. Clinical 
presentation played only a minor role in determining 
healthcare access and antibiotic use.
Conclusions This study underlines the importance of 
context and local livelihoods in tackling drug resistance. 
While supporting the growing emphasis on AMR- sensitive 
development policy, we call for future research to study 
systematically the healthcare- seeking behaviour impact 
of precarious livelihoods, social policy and community 
development initiatives.
Trial registration number NCT03241316.
BACKGROUND
Global health research and practice have 
become increasingly sensitive to non- clinical 
factors that influence health outcomes. This 
recognition has been driven by the concepts 
of the ‘social determinants of health’ and 
‘diseases of poverty’,1–3 which draw attention 
to the role of the local context in the response 
to global health priorities. Antimicrobial 
resistance (AMR) is one of these priorities, 
feared to become one of the leading global 
causes of death by 20504—and we here study 
Key questions
What is already known?
 ► Precarity is an important social determinant of health 
with demonstrated physical and mental health con-
sequences, which affects people in low- income, 
middle- income and high- income contexts.
 ► The response to antimicrobial resistance (AMR) in 
human use focuses heavily on individual behaviour 
change, neglecting the critical role that contextual 
determinants play in behaviours of individuals.
 ► The behavioural impact of precarious livelihoods is 
hypothesised to contribute to clinically inadvisable 
antibiotic use and therefore potentially to AMR.
What are the new findings?
 ► We used an original micro- level behavioural data 
set from Thailand and Lao People’s Democratic 
Republic, which enabled us to disentangle clinical 
presentation, marginalisation and precarity as sepa-
rate drivers of healthcare- seeking behaviour.
 ► The link between clinical presentation and antibiotic 
use was surprisingly weak. Instead, patients in pre-
carious circumstances were significantly more likely 
to misuse antibiotics in the presence of situational 
facilitators (eg, mobile phones and social support 
activated during an illness).
 ► This is the first study that examined quantitatively 
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the role of precarity as a contextual factor shaping 
patients’ healthcare- seeking behaviour with reference to 
AMR (we define precarity as ‘a form of pernicious self- 
dependence that undermines individuals’ control over 
their own lives and limits their ability to flexibly respond 
to crises’—that is, a condition driven by contextual factors 
that deprive people of predictability and stability of their 
lives; see further explanation below).
One key domain of demand- side responses to AMR is 
population behaviour change towards a more targeted 
use of antimicrobials such as antibiotics (in line with 
clinical presentation).5 With education and awareness 
campaigns being key policy instruments,5 6 the behaviour 
change approach in AMR assumes that the main drivers 
of behaviour are patient misconceptions and a lack of 
knowledge.7–10 However, the link between antibiotic use 
and people’s ‘awareness’ of drug resistance (and their 
level of education more generally) is more complicated 
than is often assumed in AMR policy documents.11–15 
In addition, an approach that foregrounds awareness 
and education also implicitly prioritises individual over 
contextual factors of healthcare- seeking behaviour—
such as precarity.
In a growing and interdisciplinary body of litera-
ture, precarity has been receiving attention as a social 
determinant of health,16 17 linked especially to employ-
ment and working conditions.3 18 19 Driven by stress 
and economic insecurity, it is argued that work- related 
precarity contributes to physical and mental illness and, 
ultimately, to premature mortality.1 3 17 Outside of public 
health, Butler20 describes precarity as the unfair distri-
bution of social, economic and political structures that 
could protect people from ‘disease, poverty, starvation, 
displacement and (…) exposure to violence’.20 Examples 
of precarity- inducing circumstances defined thus include 
oppressive gender norms and experiences of ‘disempow-
erment’.21 22
Patients in such circumstances could find themselves 
pressured into detrimental patterns of self- medication 
and delayed healthcare access. Consequently, ‘quick fix’ 
solutions such as self- medication or antibiotic purchase 
without prescriptions can be interpreted as default 
strategies to cope with adversity,23–25 or perhaps even as 
‘performance enhancers’.26 Precarity could therefore 
challenge the underlying assumptions and ultimately the 
effectiveness of public awareness campaigns that form 
the backbone of global AMR strategies (‘Only take anti-
biotics prescribed to you’).4 8 27 However, and despite the 
growing body of work, evidence evaluating contextual 
factors leading to precarity against the backdrop of AMR 
is limited (empirical research has studied the broader 
link between precarity and health but with a tendency 
to focus on high- income contexts28–30). In response, we 
investigated two research questions against the back-
drop of AMR: ‘What is the impact of precarity, margin-
alisation and clinical presentation on healthcare- seeking 
behaviour?’ We subsequently explored whether these 
patterns of healthcare- seeking behaviour are justified in 
light of patients’ clinical presentation: ‘Do patients expe-
riencing precarious livelihoods have clinically less advis-
able healthcare- seeking behaviour?’
We situated our research in rural Thailand and Lao 
People’s Democratic Republic (PDR), considering that 
Southeast Asia is an epicentre for antibiotic resistance.31–34 
Rural settings are of particular relevance because their 
health systems face heightened infrastructural, human 
resource, and financial challenges and a high burden of 
communicable diseases.35–38 Precarity in various forms 
has been highlighted in the region as well,39 40 whereby 
large parts of working populations remain excluded from 
social welfare schemes; informal agricultural work alter-
nates with off- season casual labour (eg, in factories) and 
gradual environmental degradation and the expanded 
presence of industry and international companies exac-
erbate precarious livelihoods.41–44 These circumstances 
have been associated with potentially detrimental forms 
of healthcare- seeking behaviour, such as unsupervised 
self- medication.45
METHODS
Study sites and population
Compared with Lao PDR, Thailand exhibited a more 
advanced economic and health system context, evidenced 
by virtually zero extreme monetary poverty at US$1.90/
day (Lao PDR: 23%), government healthcare expendi-
ture of 15% of total government expenditure (Lao PDR: 
4%) and an expected life expectancy at birth of 75 years 
(Lao PDR: 67 years) (2017 data from World Bank46). Thai-
land also had a more established AMR strategy, which was 
evident in a national action plan on AMR together with a 
network of 74 surveillance sites—neither of which existed 
in Lao PDR at the time of this research.34
Our study population was the general adult popula-
tion of rural Chiang Rai province, Thailand, and Salavan 
province, Lao PDR. The specific study sites comprised 
five villages (three in Chiang Rai, two in Salavan), which 
were selected in consultation with local stakeholders. 
Guiding selection criteria were (1) village size and struc-
ture, (2) remoteness, (3) village- level infrastructure, (4) 
ethnic composition and (5) available health facilities. 
Key questions
What do the new findings imply?
 ► Development processes that change whether and how people ex-
perience precarious circumstances could have unforeseen implica-
tions for collective global health threats such as AMR.
 ► Our study lends support to ‘AMR- sensitive development policy’: 
global health interventions must move beyond patient- centric and 
disease- centric approaches, acknowledging and responding to 
contextual factors that shape how people cope with illness.
 ► If precarity as a social determinant continues to be neglected, then 
localised forms of hardship could unwittingly influence and under-
mine the effectiveness of existing clinical and behavioural interven-
tions to tackle AMR.
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The villages had an estimated population between 339 
and 1462 residents (including children; estimates based 
on enumeration roster data), representing 3331 villagers 
in total (1125 in Chiang Rai, Thailand; 2206 in Salavan, 
Lao PDR).
Patient and public involvement
This project was based on preceding qualitative research 
with local northern Thai patients and the general 
public,47 48 which revealed the need for sociomedical 
research on patient experiences of illness in context. 








scores)* Variable descriptionMean 95% CI Mean 95% CI
Outcome variables
  Access 66% 0.62 to 0.69 90% 0.88 to 0.92 121.66*** Binary variable: patient accessed any kind 
of informal/formal care (1=yes)
  Antibiotic 15% 0.13 to 0.18 39% 0.36 to 0.43 97.18*** Binary variable: antibiotic use during illness 
(1=yes)
  Inadvisable_Access 28% 0.25 to 0.32 38% 0.35 to 0.42 14.73*** Binary variable: formal healthcare access 
without indication or vice versa
  Inadvisable_Antibiotic 11% 0.09 to 0.14 22% 0.19 to 0.25 29.69*** Binary variable: antibiotic use without 
indication or vice versa, or antibiotic use 
from informal sources
Clinical presentation
  Sepsis 57% 0.53 to 0.61 71% 0.67 to 0.74 28.50*** Binary variable: presence of an infection
  Respi 56% 0.52 to 0.59 73% 0.70 to 0.76 45.02*** Binary variable: respiratory presentation 
(incl. common cold)
  Common_Cold 34% 0.31 to 0.38 38% 0.35 to 0.42 2.17 Binary variable: common cold
  Fever 20% 0.17 to 0.23 30% 0.27 to 0.33 16.83*** Binary variable: fever
  Neuro 12% 0.09 to 0.14 24% 0.21 to 0.27 33.49*** Binary variable: neurological presentation
  Digest 16% 0.14 to 0.19 14% 0.12 to 0.16 1.58 Binary variable: digestive presentation
  Uro_Gyneco 1% 0.00 to 0.02 2% 0.01 to 0.03 0.80 Binary variable: uro- gynaecological 
presentation
  Trauma_Pain 16% 0.13 to 0.18 11% 0.08 to 0.13 7.77*** Binary variable: traumatism
  Other 07% 0.05 to 0.09 3% 0.02 to 0.04 10.97*** Binary variable: other symptoms
  Duration_Symptoms 1.48 1.44 to 1.53 1.36 1.32 to 1.39 4.02*** Categorical variable: duration of symptoms 
(1 =<7 days; 2=7–30 days; 3=>30 days)
  Severity 1.79 1.73 to 1.85 1.82 1.77 to 1.87 −1.26 Categorical variable: symptom severity 
grade (1=low; 2=moderate; 3=severe)
  Frequency 49% 0.45 to 0.53 35% 0.31 to 0.38 30.31*** Binary variable: repeated illness of patient 
within 6 months (1=yes)
Other independent variables
  Precarity_index 0.39 0.38 to 0.41 0.34 0.33 to 0.35 5.86*** Discrete variable: precarity index 
(composed of six individual indicators)
  Marginalisation_index 0.56 0.53 to 0.59 0.06 0.05 to 0.07 26.69*** Discrete variable: marginalisation index 
(composed of three individual indicators)
  Facilitation_index 0.38 0.36 to 0.41 0.26 0.24 to 0.28 7.48*** Discrete variable: facilitation index 
(composed of three individual indicators)
  Control_adult 20% 0.17 to 0.23 38% 0.35 to 0.41 55.68*** Binary variable: illness of adult or child 
(0=adult, 1=<18 years)
  Control_sex 57% 0.54 to 0.61 64% 0.60 to 0.67 5.75** Binary variable: sex of respondent 
(1=female)
  Control_distance 6.00 5.91 to 6.09 0.49 0.46 to 0.52 32.40*** Continuous variable: distance to nearest 
formal healthcare provider (km)
Illness- level data, including only completed illnesses experienced by respondent or a child under their supervision. Unweighted statistics.
Source: authors, based on survey data.
Χ2 test scores for binary variables and z- scores for Wilcoxon rank- sum tests for other non- normally distributed variables (Duration_Symptoms, 
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In this particular project, members of the Thai and Lao 
public were involved through cognitive interviewing to 
inform the survey design and through local workshops to 
improve our understanding of local medicine uses and 
healthcare- seeking behaviour.
Survey design and implementation
We implemented two- round individual- level census 
surveys in the five purposively selected villages between 
November 2017 and May 2018. Within the selected 
communities, all households were enumerated using 
a satellite- aided sampling approach,49 and all adults 
(aged at least 18 years) were invited to participate. Our 
household definition was based on a shared kitchen and 
previous residence of at least 6 months in the survey 
village. The household response rate in the first survey 
round was 97.9%, and 99.1% in the second survey round 
(745 and 754 out of 761 households, respectively). A total 
of 2066 adult villagers were interviewed, whereby 88.8% 
(1678/1890) of the first- round participants could be 
re- interviewed (taking into consideration non- response 
and seasonal migration).
We chose an oral consent procedure to not alienate 
and discriminate against illiterate or unregistered partic-
ipants. Of the 3744 responses across the two survey 
rounds, we did not receive consent for data sharing in 
four instances, which constitutes the main difference 
between the data analysed here and the publicly avail-
able data set of our project.50 The recruitment and data 
collection processes were monitored in the field through 
the survey supervisors, a research officer and digital 
survey monitoring tools. 15.0% (560/3744) of all inter-
view sessions were monitored by a survey supervisor.
Based on the complete village census, we identified as 
patients those respondents who had an acute illness and 
injury in the 2 months preceding the survey (or children 
below 18 years who experienced an illness episode under 
the respondents’ supervision).
Survey instrument
Our survey instrument was a 45- min face- to- face ques-
tionnaire (see online supplemental file 2), adminis-
tered on tablet computers using SurveyCTO.51 The 
locally recruited field teams received 5 days of full- time 
classroom and field training (plus an additional 5 days 
for supervisors). The questionnaire was piloted in rural 
Chiang Rai and Salavan, with 50 cognitive interviews 
supporting the questionnaire development and revision 
as well as the contextualisation of the survey data (not 
reported here).52 The questionnaire was co- developed 
with the local research team in English, Thai and Lao, 
administered in the local language (Thai/Lao), and 
translation difficulties with ethnic minority languages 
were resolved by recruiting local translators within the 
survey villages.
The questionnaire modules included (1) basic demo-
graphic and socioeconomic information, (2) social 
network structures, (3) antibiotic- related knowledge and 
attitudes and (4) healthcare- seeking behaviour during 
acute illnesses and accident- related injuries. This study 
used in particular modules 1 and 4, whereby 60.8% 
(1256/2066) of the participants volunteered information 
about at least one recent illness episode, experienced 
by themselves or a child under their supervision within 
the 2 months preceding the survey, yielding a total of 
1887 illness episodes captured by the community census 
surveys (1421 episodes after removing ongoing/yet unre-
solved illnesses).
The healthcare- seeking data included self- reported 
symptoms and recalled diagnosis of the condition as well 
as detailed information about each step of the illness 
episode, from the moment a discomfort was detected 
until the condition was resolved or the symptoms other-
wise disappeared. For every step, the type of treatment 
was recorded (including ‘ignoring’ the condition, 
self- care and care from family and friends, and various 
locally specific forms of informal and formal treat-
ment) together with the type of received medication (as 
Figure 1 (A) Access to healthcare and (B) antibiotic intake 
according to clinical determinants in Chiang Rai and Salavan. 
Source: authors, based on survey data. Notes: OR adjusted 
by precarity, marginalisation, facilitation, duration, frequency 
and severity of symptoms, gender, age category, distance 
to the nearest formal healthcare and by cluster, using a site- 
fixed control variable. Error bars indicate 95% CI.
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recalled by respondent) and supplementary information 
about the process (eg, mode of transport to reach point 
of care). This information formed the basis for our anal-
ysis of healthcare- seeking behaviour: on the one hand, 
these data documented ‘revealed’ healthcare- seeking 
behaviour during the course of an illness episode (we 
focused here specifically on whether formal healthcare 
access took place and on the medicine that patients 
received during the illness episodes). On the other hand, 
the rich information on self- described symptoms and 
recalled diagnoses (which we discussed and interpreted 
together with the local research teams) permitted a 
broad categorisation of clinical presentation (see online 
supplemental table 1) and—together with information 
on disease severity, duration and recurrence along-
side the revealed healthcare- seeking behaviour of the 
patient—enabled a basic clinical evaluation by our medi-
cally qualified research team member (TA; described in 
more detail below).
Considering the importance of antibiotics for our 
research question, we focused on cases where we could 
establish antibiotic use with a high degree of confidence. 
We manually coded free- text responses of reported medi-
cines and treatments based on pharmaceuticals in local 
circulation, and triangulated ambiguous responses (eg, 
‘germ killer’) based on respondents’ reports as to how 
they colloquially refer to antibiotics in module 3 of the 
survey questionnaire. Of all 4611 recorded medicine use 
episodes, 13.5% (623/4611) involved an antibiotic with 
a high degree of confidence (8.2% of all illness episodes 
did not involve any form of treatment, while 23.3% could 
not be classified as either antibiotic or non- antibiotic—
eg, ‘white powder’ or ‘green capsule’—given the avail-
able information).
Determinants of healthcare-seeking behaviour
The key independent variables comprise clinical deter-
minants and composite indexes of precarity, marginali-
sation and situational facilitation. We explain these vari-
ables below and provide variable summaries in online 
supplemental table 2.
Clinical determinants
The impact of each clinical determinants, their duration, 
severity (mild, moderate and severe) and frequency over 
the past 6 months was evaluated on healthcare- seeking 
behaviour. The nine clinical determinants were based 
on respondents’ reported symptoms and recalled diag-
nosis during medical encounters, and included pres-
ence of an infection, fever, respiratory tract symptoms, 
Table 2 Determinants of healthcare- seeking behaviour
Dependent variable Access (any access to healthcare) Antibiotic (antibiotic use during illness)
Model type No interaction Interaction model No interaction Interaction model
Model number (1) (2) (3) (4)
Marginalisation_index 1.02 (0.52 to 1.97) 1.03 (0.53 to 2.00) 0.31*** (0.16 to 0.60) 0.31*** (0.16 to 0.60)
Precarity_index 2.37* (0.92 to 6.10) 3.88** (1.11 to 13.58) 0.71 (0.33 to 1.56) 0.36* (0.11 to 1.21)
Facilitation_index 17.49*** (8.95 to 34.18) 40.50*** (8.39 to 195.59) 1.95*** (1.21 to 3.14) 0.96 (0.33 to 2.79)
Precarity_index # Facilitation_index 0.11 (0.00 to 4.43) 7.71 (0.49 to 120.87)
Control_adult (ref: adult) 4.60*** (2.86 to 7.41) 4.64*** (2.88 to 7.48) 1.57*** (1.20 to 2.05) 1.58*** (1.21 to 2.06)
Control_sex (ref: male) 0.97 (0.71 to 1.33) 0.97 (0.71 to 1.32) 1.25* (0.96 to 1.63) 1.26* (0.97 to 1.65)
Control_distance 0.94 (0.78 to 1.14) 0.94 (0.77 to 1.14) 0.93 (0.77 to 1.12) 0.93 (0.77 to 1.12)
Duration_Symptoms (ref: <7 days)
  7–30 days 2.40*** (1.66 to 3.46) 2.42*** (1.67 to 3.50) 1.72*** (1.31 to 2.25) 1.71*** (1.31 to 2.24)
  >30 days 0.97 (0.43 to 2.18) 0.96 (0.43 to 2.17) 0.72 (0.35 to 1.51) 0.73 (0.35 to 1.53)
Frequency (ref: no repeat illness) 1.04 (0.76 to 1.42) 1.03 (0.75 to 1.40) 1.05 (0.81 to 1.35) 1.05 (0.81 to 1.36)
Severity (ref: low)
  Moderate 2.00*** (1.43 to 2.78) 1.98*** (1.42 to 2.75) 1.26 (0.95 to 1.68) 1.28* (0.96 to 1.70)
  Severe 3.84*** (2.28 to 6.49) 3.82*** (2.26 to 6.46) 1.61*** (1.12 to 2.32) 1.63*** (1.13 to 2.34)
Site (ref: Chiang Rai) 4.94*** (1.84 to 13.27) 4.99*** (1.86 to 13.42) 1.52 (0.59 to 3.89) 1.53 (0.60 to 3.93)
Constant 0.01*** (0.00 to 0.10) 0.01*** (0.00 to 0.09) 0.09** (0.01 to 0.68) 0.11** (0.01 to 0.84)
Observations 1421 1421 1421 1421
P value <0.01 <0.01 <0.01 <0.01
AIC 1075.27 1075.91 1542.65 1542.53
Source: authors, based on survey data.
Illness- level data, including only completed illnesses experienced by respondent or a child under their supervision. Unweighted statistics. ORs 
adjusted by all covariates. 95% CIs in brackets.
*p<0.10, **p<0.05, ***p<0.01.
AIC, Akaike Information Criterion.
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common cold (defined as the presence of runny nose 
and/or sneezing and/or cough), digestive symptoms, 
uro- gynaecological symptoms, neurological symptoms, 
traumatism and other symptoms. For full disclosure, the 
complete list of symptoms and their coding into clinical 
presentation is provided in online supplemental table 1.
Precarity
The health impact of precarity is often framed in similar 
terms as problematic employment conditions, poverty/
marginalisation (which are often used synonymously) or 
stress.1 3 17 53 54 Based on our definition, however, we argue 
that precarity is a phenomenon with distinct behavioural 
implications. Precarity differs from poverty and marginal-
isation (which are often used as synonyms in the context 
of multidimensional deprivation), because it can be expe-
rienced regardless of wealth level (in middle- income and 
high- income contexts as well as among populations that 
are not conventionally deemed ‘poor’),55–59 and it may 
have different impacts on healthcare- seeking behaviour 
than the ‘barriers’ created by marginalisation (eg, living 
far away from a healthcare unit54 60). In relation to stress 
Table 3 Determinants of clinically inadvisable healthcare access and antibiotic use
Dependent variable
Inadvisable_Access (formal healthcare access 
without indication or vice versa)
Inadvisable_Antibiotic (antibiotic use without 
indication or vice versa, or antibiotic use from 
informal sources)
Model type No interaction Interaction model No interaction Interaction model
Model number (1) (2) (3) (4)
Marginalisation_index 1.04 (0.60 to 1.78) 1.04 (0.61 to 1.79) 0.61 (0.30 to 1.26) 0.61 (0.29 to 1.26)
Precarity_index 1.88* (0.92 to 3.85) 1.23 (0.45 to 3.39) 0.69 (0.28 to 1.68) 0.21** (0.05 to 0.80)
Facilitation_index 0.33*** (0.21 to 0.52) 0.18*** (0.06 to 0.55) 1.67* (0.98 to 2.86) 0.47 (0.14 to 1.58)
Precarity_index # Facilitation_
index
4.83 (0.34 to 68.73) 37.89** (1.75 to 818.45)
Control_adult (ref: adult) 0.94 (0.72 to 1.22) 0.94 (0.72 to 1.22) 1.04 (0.76 to 1.42) 1.05 (0.76 to 1.43)
Control_sex (ref: male) 1.01 (0.80 to 1.29) 1.02 (0.80 to 1.29) 1.10 (0.82 to 1.49) 1.12 (0.83 to 1.52)
Control_distance 1.01 (0.85 to 1.18) 1.00 (0.85 to 1.18) 0.82* (0.67 to 1.02) 0.82* (0.66 to 1.02)
Duration_Symptoms (ref: 
<7 days)
  7–30 days 0.74** (0.57 to 0.95) 0.74** (0.57 to 0.95) 1.51*** (1.11 to 2.05) 1.50*** (1.11 to 2.04)
  >30 days 0.50* (0.24 to 1.04) 0.51* (0.24 to 1.05) 1.22 (0.57 to 2.57) 1.25 (0.59 to 2.64)
Frequency (ref: no repeat 
illness)
1.14 (0.90 to 1.44) 1.14 (0.91 to 1.45) 0.93 (0.70 to 1.25) 0.94 (0.70 to 1.25)
Severity (ref: low)
  Moderate 0.61*** (0.48 to 0.79) 0.62*** (0.48 to 0.80) 1.00 (0.72 to 1.38) 1.02 (0.74 to 1.41)
  Severe 0.64** (0.45 to 0.90) 0.64** (0.45 to 0.90) 1.04 (0.69 to 1.58) 1.06 (0.70 to 1.60)
Site (ref: Chiang Rai) 1.59 (0.69 to 3.66) 1.59 (0.69 to 3.67) 0.69 (0.24 to 1.98) 0.70 (0.24 to 2.01)
Constant 0.60 (0.23 to 1.57) 0.70 (0.26 to 1.89) 0.38 (0.11 to 1.26) 0.55 (0.16 to 1.91)
Observations 1421 1421 1421 1421
P value <0.01 <0.01 <0.01 <0.01
AIC 1758.07 1758.72 1282.86 1279.49
Source: authors, based on survey data.
Illness- level data, including only completed illnesses experienced by respondent or a child under their supervision. Unweighted statistics. ORs 
adjusted by all covariates. 95% CIs in brackets.
*p<0.10, **p<0.05, ***p<0.01.
AIC, Akaike Information Criterion.
Figure 2 Predicted moderation effect of facilitation on 
the relationship between precarity index and clinically 
inadvisable antibiotic use. Source: authors, based on survey 
data. Notes: predicted and interpolated results on basis of 
model 4 in table 3, controlling for marginalisation, clinical 
determinants, field site and other control variables. Shaded 
areas indicate 95% CIs.
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(which often leads precarity to be represented by employ-
ment conditions), it is important to note that the behav-
ioural influence of precarity only partly overlaps with 
stress experienced in problematic employment or under 
conditions of poverty.61 62 More broadly, the behavioural 
impact of precarity may be better described as a ‘loss 
of control and flexibility’ over health- related decisions, 
which extends beyond employment and also involves for 
instance community- level social support.21 25 63
In order to represent the distinct circumstances under 
which precarity could militate against healthcare- seeking 
behaviour, we considered six indicators along occupa-
tional, social and logistical dimensions. The occupa-
tional dimension clearly cannot be ignored in a study 
of precarity and evaluated whether (1) people’s income 
was erratic (eg, no formal employment contract or 
regular income) and whether (2) the structure of the 
work restricted people’s flexibility when responding to 
illnesses (daily labourers and agriculturalists).25 30 The 
social dimension of precarity was evaluated through the 
(3) absence of other adults in the households and (4) 
the lack of a health- related social network (in terms of 
regular exchange of health advice38 64 65). Lastly, logis-
tical indicators comprised the absence of solutions to 
flexibly address health problems, namely (5) no house-
hold mobile phone (as consistent predictor of individual 
non- use of mobile phones during an illness66) and (6) no 
motor transport option within the household (including 
motorcycles/tricycles, cars or tractors).
Marginalisation
Marginalisation was evaluated in terms of education, 
wealth and ethnicity60 67: (1) the respondent had not 
received any formal education, (2) belonged to the lowest 
household asset quintile among the rural population in 
their province and (3) did not belong to the majority 
Thai/Lao Loum ethnic groups in their field sites (who 
might also speak different languages). Although spatial 
marginalisation would also be an important dimension 
to consider, we chose not to include it into the index 
considering that distances to health facilities were similar 
and clustered at the village level. The respondents’ 
distance to the nearest formal health facility was thus 
included as a separate control variable,38 67 alongside 
other controls including the sex of the respondent and 
whether the reported illness episode was experienced by 
the respondent themselves or a child (below 18 years of 
age) under their supervision.21 67
Facilitation
In addition to the indicators above, situations and prac-
tical means may arise situationally—that is, revealed 
during the course of an illness—which enable patients 
to respond to crisis and escape the structural conditions 
of precarity and marginalisation.21 68 Our survey detected 
such ‘situational facilitators’ in the form of tools and 
support sources that become visible during an illness 
episode: (1) support received from other people during 
the illness episode, (2) health- related phone use during 
the illness (not necessarily by the patient themselves) and 
(3) the use of a car or taxi during the illness (eg, from 
a neighbour). These situational facilitators could help 
mitigate structural conditions of precarity, as a result of 
which we analyse them separately and in interaction with 
our precarity index.
Behavioural outcomes
Outcome variables considered in this study comprised 
different forms of access to healthcare and antibiotic use 
to represent healthcare- seeking behaviour. Reflecting 
the pluralistic health systems of Southeast Asia,69 health-
care access (outcome variable ‘Access’) included formal 
healthcare providers (public primary care units, hospitals, 
private clinics) and informal sources of care (pharma-
cies, unlicensed private practitioners, traditional healers, 
grocery stores, family members and friends). Antibiotic 
use (outcome variable ‘Antibiotic’) captured whether 
any antibiotic was received at any point during the illness 
episode (including antibiotics stored at home).
We complemented the analysis of healthcare- seeking 
behaviour with an evaluation of clinically ‘inadvisable’ 
antibiotic use and healthcare access. These evaluations 
used the comprehensive survey data surrounding patient 
clinical presentation (symptoms, symptom severity, dura-
tion, recurrence), which enabled us to identify cases in 
which healthcare access and antibiotic use appeared 
clinically advisable but was not pursued (or vice versa). 
Given the nature of the self- reported data, we did not flag 
behaviours as ‘inadvisable’ where the clinical indication 
was unclear. The evaluation was carried out by a medi-
cally qualified co- author with research experience in the 
field sites (TA) in correspondence with the local research 
teams.
Specifically, the first clinical indicator (outcome vari-
able ‘Inadvisable_Access’) evaluated the rationale for 
seeking no formal treatment despite a clear indication 
for care, and vice versa. The second clinical indicator 
evaluated the rationale for antibiotic use (outcome vari-
able ‘Inadvisable_Antibiotic’), whereby our focus was on 
identifying situations with a clear indication to not use 
an antibiotic, namely scrub typhus, leptospirosis, cholera 
and malaria. We also flagged as inadvisable where 
patients used antibiotics despite the absence of a clear 
indication for an antibiotic (namely common cold, docu-
mented viral or fungal or parasitic illness, chronic pain 
and bone trauma) and when patients accessed antibiotics 
stored at home, from friends, traditional healers and 
other unregulated sources of healthcare (6% or 83/1421 
illness episodes; robustness checks focusing only on clin-
ical indication reproduced the results and were omitted 
from reporting.)
Note that these evaluations are strictly from a clinical 
perspective and do not entail judging villagers’ behaviour 
as ‘unreasonable’—our argument rather is that people 
have good reasons and structural determinants for 
behaving the way they do, and that this behaviour might 
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look clinically inappropriate but requires non- clinical 
responses.
Analytical strategy
The analysis took place on the illness level, whereby 
we analysed the pooled sample of all completed illness 
episodes across the two survey rounds. We proceeded in 
four steps:
 ► Step 1: descriptive analysis of the healthcare- seeking 
behaviour, precarity and marginalisation among the 
study population.
 ► Step 2: contribution of the clinical determinants on 
healthcare- seeking behaviour.
 ► Step 3: contribution of precarity and marginalisation 
on healthcare- seeking behaviour.
 ► Step 4: the role of precarity as contributor to clinically 
inadvisable healthcare access and antibiotic use.
Step 1 was based on descriptive statistical analysis to 
describe and contrast the survey results across the two 
field sites. We compared the samples on the illness level, 
using χ2 tests for binary and Wilcoxon rank- sum tests 
(two- sided) for non- normally distributed variables to test 
for differences across sites.70 71
We conducted univariate and multivariate regression 
analyses for Steps 2–4 (see online supplemental file 1 for 
a description of the statistical models). For Step 2, we 
focused on the contribution of the clinical presentation 
to the healthcare- seeking outcomes (access to healthcare, 
antibiotic use). For each outcome, we separately esti-
mated the contribution of the eight clinical presentations 
(excluding the heterogeneous group of ‘other symp-
toms’), controlling for symptom duration, severity and 
illness frequency as well as other confounding variables 
(see full variable list in online supplemental table 2). Step 
3 assessed the relative contribution of precarity, facilita-
tion and marginalisation to the outcomes of healthcare 
access and antibiotic use (excluding specific symptoms 
for simplicity but retaining other clinical determinants 
as control variables). In Step 4, we analysed whether 
precarity in isolation or moderated by situational facil-
itators contributes to healthcare- seeking behaviour that 
appears clinically less desirable (‘Inadvisable_Antibiotic’ 
and ‘Inadvisable_Access’), again controlling for clinical 
determinants and other control variables.
For all analyses in Steps 2–4, we first conducted univar-
iate analyses, followed by multivariate analyses adjusted 
by confounders (the main results only contain multivar-
iate results for simplicity). We initially chose multilevel 
logistic regression models with a site random effect.72 
However, in several instances, the maximum likelihood 
estimation of the multilevel models failed to converge 
and to produce SE estimates,73 as a result of which we 
limited the presentation of the main results to single- 
level models with a site dummy.
We also conducted the multivariate analysis with an 
interaction effect between precarity index and facilita-
tion index to consider the potential moderating effect 
of the situational facilitators. We compared model fitness 
between the interacting and non- interacting models 
based on the significance levels of the parameter estimate 
for the interaction term and the Akaike Information 
Criterion (AIC74), reporting interacting models where 
the interaction term was statistically significant (p<0.05) 
and AIC was smaller than the non- interacted model.
Our robustness checks (not reported here) included 
comparisons between the single- level and multilevel 
models and estimations using nested models and 
including patients’ symptoms as additional determi-
nants of health behaviour. The robustness checks did not 
substantively influence the main results nor the conclu-
sions of this paper.
We used the statistical software Stata V.15 (StataCorp). 
Throughout the results, we indicated significance levels 
below 0.1, 0.05 and 0.01 with *, ** and ***, respectively, 
and considered the 5% level as ‘statistically significant’.
RESULTS
Step 1: patterns of illness, precarity and marginalisation
Across the 1421 illness episodes in the sample (625 in 
Chiang Rai and 796 in Salavan), the most commonly 
reported illness was the presence of any infection with 
64.6% (918/1421) of all cases, while the term ‘fever’ was 
cited in 25.7% (365/1421) of all cases. Respiratory tract 
symptoms were the second most reported complaint 
(65.1%, 925/1421 cases), of which common cold repre-
sented 56% (519/925 cases). Median duration of symp-
toms was 5 days (IQR 3–8), with a moderate severity. 
79.2% (1125/1421) of illnesses involved access to health-
care and antibiotic intake was declared in 28.7% of all 
cases (408/1421).
The results of the descriptive statistical comparison of 
the two field sites are presented in table 1. The compar-
ison indicated that illness episodes were statistically 
significantly more likely to involve healthcare access 
and antibiotic use in Salavan, where healthcare- seeking 
behaviour was also more commonly misaligned with 
patients’ clinical presentation. The most common forms 
of clinical presentation in both sites were the presence 
of an infection, followed by respiratory tract symptoms 
(with common cold as the most frequent component) 
and the declaration of fever. Furthermore, precarity 
and marginalisation were more concentrated among 
the patients in Chiang Rai, as indicated by the relatively 
higher average precarity scores (0.39 vs 0.35, p<0.01) and 
marginalisation scores (0.56 vs 0.06, p<0.01). While not 
necessarily representative of the overall provincial popu-
lation,15 these statistics reflect the living conditions of the 
specific field site communities.
Step 2: clinical determinants and healthcare-seeking 
behaviour
In the multivariate analysis of clinical determinants, 
the common cold was the only clinical presentation 
significantly associated with healthcare access (83.2% 
(432/519) of all common cold episodes; adjusted OR 
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(aOR) 1.63 (95% CI: 1.17 to 2.26)). However, antibiotic 
intake for common cold was not significantly greater 
than other clinical presentations (aOR 1.15, 95% CI: 0.89 
to 1.48), whereas the presence of an infection was signifi-
cantly associated with antibiotic intake (32.5%, 298/918, 
aOR 1.44, 95% CI: 1.09 to 1.91), as was respiratory tract 
infection (33.1%, 306/925, aOR 1.64, 95% CI: 1.23 to 
2.18). The presence of digestive symptoms was signif-
icantly associated with antibiotic withholding (22.8%, 
49/215, aOR 0.60, 95% CI: 0.41 to 0.87). The association 
between clinical determinants and outcomes is illus-
trated in figure 1, with detailed results provided in online 
supplemental tables 3 and 4.
Step 3: marginalisation and precarity as determinants of 
healthcare-seeking behaviour
Table 2 presents the results of the regression analysis, 
controlling in all cases for a reduced set of clinical deter-
minants (duration, frequency and severity of symptoms) 
and considering the potential moderating role of situ-
ational facilitators in the interaction models (models 2 
and 4).
The interaction terms were not statistically significant 
for healthcare access and antibiotic use. Instead, facilita-
tion presented a strong and statistically significant positive 
association with healthcare access (aOR 17.49, 95% CI: 
8.95 to 34.18) and antibiotic use (aOR 1.95, 95% CI: 1.21 
to 3.14) independently of precarity. The marginalisation 
index was associated with antibiotic withholding at the 
1% level (aOR 0.31, 95% CI: 0.16 to 0.60), whereas the 
precarity index was not statistically significantly associ-
ated with healthcare access or antibiotic use. Among 
other control variables, illnesses involving children, those 
with a higher severity rating and illnesses with a duration 
between 7 and 30 days were significantly more likely to 
involve healthcare access and antibiotic use.
Step 4: precarity and clinically inadvisable healthcare-
seeking behaviour
This final step assessed the factors contributing to clin-
ically advisable healthcare- seeking behaviour (table 3). 
The interaction term was statistically significant at the 
five- percent level for the antibiotic use model. No statis-
tically significant association existed between marginal-
isation and the dependent variables, whereas a signif-
icant association existed between precarity and ‘Inad-
visable_Antibiotic’ through the interaction term. The 
statistically significant interaction term suggests that the 
association between precarity and inadvisable antibiotic 
use increased with higher levels of facilitation. Facilita-
tion was also associated with more advisable patterns of 
healthcare access (model 1, aOR 0.33, 95% CI: 0.21 to 
0.52).
Figure 2 summarises the key findings from this analysis 
and illustrates that, in the absence of situational facilita-
tors, higher degrees of precarity were predicted to link to 
more appropriate antibiotic access patterns (from a clin-
ical perspective; indicating lower overuse of antibiotics). 
Simultaneously, patients exhibiting facilitation through 
mobile phones, motor transport or human support 
were predicted to be at higher risk of clinically inadvis-
able antibiotic use when being in otherwise precarious 
circumstances. For the highest levels of the precarity, the 
predicted difference between patients with and without 
facilitation in inadvisable antibiotic use was 44.9% points. 
In contrast, patients with a precarity index of zero were 
10.3% points less likely to misuse antibiotic if they experi-
enced the full range of facilitators captured in our survey.
DISCUSSION
Our research focused on the clinical and socioeconomic 
determinants of healthcare- seeking behaviour. We drew 
on a uniquely detailed health behaviour census survey 
from five villages across northern Thailand (Chiang Rai 
province) and southern Lao PDR (Salavan province) as 
part of a broader healthcare- seeking behaviour research 
project.35 Data from 2066 villagers across five communi-
ties included 1421 completed episodes of acute illnesses 
and injuries over the period of 6 months. Our four- step 
analysis offered the following interpretations:
1. Patients commonly exhibited respiratory tract symp-
toms, presence of an infection and fever. Precarious 
livelihoods were common in both sites, whereas in-
dication of marginalisation was less widespread and 
more concentrated in Chiang Rai.
2. The common cold was positively associated with 
healthcare access whereas presence of an infection 
and respiratory tract symptoms were positively associat-
ed with antibiotic use. The surprisingly minor link be-
tween clinical presentation and antibiotic use pointed 
towards the importance of other, social determinants 
of healthcare- seeking behaviour, such as precarity and 
marginalisation.
3. We analysed the contribution of marginalisation and 
precarity to healthcare- seeking behaviour and found 
that situational facilitators were associated positively 
with healthcare access and antibiotic use, but no mod-
erating effect of facilitation on precarity materialised. 
Marginalisation was negatively associated with antibi-
otic use. However, overall rates of healthcare access 
and antibiotic use could mask clinical justifications for 
the observed behaviour.
4. An evaluation of clinically inadvisable healthcare 
access and antibiotic use showed that facilitation in-
dependently linked to more appropriate healthcare 
access. In addition, controlling for other determinants 
of health behaviour, patients in otherwise precarious 
circumstances were significantly more likely to misuse 
antibiotics in the presence of situational facilitators.
To the best of our knowledge, this is the first study 
that examined quantitatively the relationship between 
precarity and AMR- related healthcare- seeking behaviour. 
A key strength of our study is the original micro- level 
behavioural data set, which enabled us to disentangle 
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clinical presentation, marginalisation and precarity as 
separate drivers of healthcare- seeking behaviour.
Key limitations in this study pertain to the nature of 
the study sample, which reflects living conditions in 
selected rural communities of Chiang Rai and Lao PDR 
rather than broader rural populations of low- income and 
middle- income countries. More extensive and system-
atic health behaviour surveys based on our in- depth 
survey instrument would be necessary to understand 
the broader variability of common healthcare- seeking 
behaviours and their socioeconomic drivers. In addi-
tion, observational survey data on healthcare- seeking 
behaviour are subject to recall biases that could amplify 
the perspectives of relatively more privileged groups.75 
However, considering complex behaviours in plural-
istic health systems,76–78 community- level studies of this 
kind are essential to complement AMR research in clin-
ical settings. Lastly, although our indicators of patients’ 
precarity and marginalisation were literature based, more 
extensive ethnographic research is necessary to identify 
their locally specific expressions, and to map out their 
links to healthcare- seeking behaviour and antimicrobial 
use.
CONCLUSIONS
The increasing health policy interest in the 2030 Sustain-
able Development Agenda79 and its relationship to global 
health priority issues such as AMR6 underlines the impor-
tance of the social determinants of health. We therefore 
studied precarity and marginalisation alongside clinical 
indication as determinants of healthcare access and anti-
biotic use, using fine- grained health behaviour survey 
data from five rural communities.
Our study has two main implications. On the one 
hand, global health interventions must move beyond 
patient- centric and disease- centric approaches, acknowl-
edging and responding to contextual factors that shape 
how people cope with illness. Interventions based on 
this logic could for instance aim at improving work 
environments, supporting social support structures and 
fostering community building. On the other hand, our 
study emphasises that localised forms of hardship could 
influence the effectiveness of clinical interventions to 
tackle AMR—an issue that is often overlooked in global 
health practice.80–82 Public health research and policy 
therefore require urgent collaboration with low- and 
middle- income country researchers and social scientists 
to appreciate the contextual drivers of global health chal-
lenges such as AMR.
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